PULSAR - A Prospective study to evaluate the Utility of Low doses of the Statins Atorvastatin and Rosuvastatin.

Study identifier:4522IL/0102

ClinicalTrials.gov identifier:NCT00329173

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 6-week open-label, randomised, multicentre, phase IIIb, parallel-group study to compare the efficacy and safety of rosuvastatin (10 mg) with atorvastatin (20 mg) in subjects with hypercholesterolaemia and either a history of CHD or clinical evidence of CHD

Medical condition

hypercholesterolaemia

Phase

Phase 3

Healthy volunteers

Study drug

Rosuvastatin, Atorvastatin

Sex

All

Actual Enrollment

1000

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 30 Nov 2003

Primary Completion Date: -

Study Completion Date: 31 Aug 2004

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Apr 2025 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

"There is no result for the study"

Documents available

Redacted CSR Synopsis
Download
Trial Results Summaries
Available here

Contacts

Investigators

Principal Investigator

Crestor Medical Science Director

AstraZeneca